Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Complement-Mediated Diseases
The 2025 update of the KDIGO IgA nephropathy guidelines: An ERA Immunonephrology Working Group perspective
PDF Split View Eleni Stamellou, Annette Bruchfeld, Fernando Caravaca-Fontan, Eleni Frangou, Andreas Kronbichler, Safak Mirioglu, Sarah M Moran, Kate I Stevens, Y K Onno Teng, Stefanie Steiger, Jürgen Floege, the Immunonephrology Working Group (IWG) of the European Renal Association (ERA), The 2025 update of the KDIGO IgA nephropathy guidelines: An ERA Immunonephrology Working Group perspective, Clinical Kidney Journal, 2025;, sfaf324, https://doi.org/10.1093/ckj/sfaf324 Close Accepted...
Disease-modifying anti-nephropathic drugs (DMANDs) - A definition proposed by the Immunonephrology Working Group (IWG) of the European Renal Association (ERA) | Nephrology Dialysis Transplantation | Oxford Academic
A definition of “disease modification“ for kidney disease is long overdue. Here, we propose three key criteria for disease modification in immune-mediated glomerulonephritis and podocytopathies: minimizing disease activity, preventing loss of kidney structure and function, and reducing treatment-related toxicity. To be considered a DMAND, a drug must fulfil all three criteria hence, the DMAND status of a drug may not be clear at the time of regulatory approval.
Antibody-mediated podocytopathies: a disease entity that implies immunotherapy
Accepted manuscripts are PDF versions of the author’s final manuscript, as accepted for publication by the journal but prior to copyediting or typesetting. They can be cited using the author(s), article title, journal title, year of online publication, and DOI. They will be replaced by the final typeset articles, which may therefore contain changes. The DOI will remain the same throughout.
Antibody-mediated podocytopathies: a disease entity that implies immunotherapy
Podocytopathies are kidney diseases in which injury to podocytes, either direct or indirect, leads to proteinuria [1]. The phenotypic characterization of podocytopathies usually reveals the presence of minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS) on kidney biopsies. These patterns of injury differ in terms of onset of disease, treatment responsiveness and subsequent long-term renal survival [2, 3].
Immunoengineering for autoimmune-kidney disease
Accepted manuscripts are PDF versions of the author’s final manuscript, as accepted for publication by the journal but prior to copyediting or typesetting. They can be cited using the author(s), article title, journal title, year of online publication, and DOI. They will be replaced by the final typeset articles, which may therefore contain changes. The DOI will remain the same throughout.
Immunoengineering for autoimmune-kidney disease
PDF Split View Safak Mirioglu, Annette Bruchfeld, Fernando Caravaca-Fontan, Gema M Fernandez-Juarez, Jürgen Floege, Eleni Frangou, Dimitrios Goumenos, Megan Griffith, Sarah M Moran, Kate I Stevens, Y K Onno Teng, Kultigin Turkmen, Andreas Kronbichler, Stefanie Steiger, on behalf of the Immunonephrology Working Group (IWG) of the European Renal Association (ERA), Immunoengineering for autoimmune-kidney disease, Nephrology Dialysis Transplantation, Volume 39, Issue 12, December 2024, Pages...
Immunoengineering for autoimmune-kidney disease
Despite recent advances in the field of immune-mediated kidney diseases, a significant proportion of patients continue to fail to achieve long-term remission and suffer from adverse events mainly arising from the use of non-targeted immunosuppressive agents. These agents, including high doses of glucocorticoids, constitute an important cause of morbidity [1].
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus
Autoreactive memory B cells contribute to chronic and progressive courses in autoimmune diseases like systemic lupus erythematosus (SLE). The efficacy of belimumab (BEL), the first approved biologic treatment for SLE and lupus nephritis (LN), is generally attributed to depletion of activated naïve B cells and inhibition of B cell activation. BEL’s effect on memory B cells (MBCs) is currently unexplained.
BIOCRYST PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) | MarketScreener
(BCRX) Delayed Nasdaq - 04:00:00 2023-05-08 pm EDT 8.490 USD -0.82% 04:40p BIOCRYST PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) AQ 05/04 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AQ 05/03 BioCryst Pharmaceuticals Q1 Loss Narrows, Revenue Rises; Shares Jump MT Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds Summary Most relevant All News Analyst Reco.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Complement-Mediated
Contact Complement-Mediated, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack